These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34505178)

  • 1. Heavy clinical and economic burden of osteoporotic fracture among elderly female Medicare beneficiaries.
    Liu J; Gong T; Xu X; Fox KM; Oates M; Gandra SR
    Osteoporos Int; 2022 Feb; 33(2):413-423. PubMed ID: 34505178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
    Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
    Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
    Liu J; Guo H; Rai P; Pinto L; Barron R
    Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
    Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
    Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
    Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
    Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
    Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
    Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of subsequent fracture after prior fracture among older women.
    Balasubramanian A; Zhang J; Chen L; Wenkert D; Daigle SG; Grauer A; Curtis JR
    Osteoporos Int; 2019 Jan; 30(1):79-92. PubMed ID: 30456571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women.
    Tran O; Silverman S; Xu X; Bonafede M; Fox K; McDermott M; Gandra S
    Osteoporos Int; 2021 Jun; 32(6):1195-1205. PubMed ID: 33411007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.
    Weaver J; Sajjan S; Lewiecki EM; Harris ST
    J Manag Care Spec Pharm; 2017 Jul; 23(7):735-744. PubMed ID: 28650253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of incident non-hip osteoporosis-related fractures in postmenopausal women from a payer perspective.
    Barcelos A; Gonçalves J; Mateus C; Canhão H; Rodrigues AM
    Osteoporos Int; 2023 Dec; 34(12):2111-2119. PubMed ID: 37596433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
    McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
    Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
    Hernandez I; Zhang Y
    J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population.
    Williams SA; Daigle SG; Weiss R; Wang Y; Arora T; Curtis JR
    Ann Pharmacother; 2021 Jul; 55(7):821-829. PubMed ID: 33148010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
    Foster SA; Shi N; Curkendall S; Stock J; Chu BC; Burge R; Diakun DR; Krege JH
    BMC Womens Health; 2013 Mar; 13():15. PubMed ID: 23521803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.
    Singer A; McClung MR; Tran O; Morrow CD; Goldstein S; Kagan R; McDermott M; Yehoshua A
    Arch Osteoporos; 2023 Mar; 18(1):42. PubMed ID: 36905559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
    Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
    Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women.
    Chandran M; Ganesan G; Tan KB; Reginster JY; Hiligsmann M
    Osteoporos Int; 2021 Jan; 32(1):133-144. PubMed ID: 32797250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.